Obermatt
See Similar Stocks →

Chugai Pharmaceutical

TYO:4519 · JP3519400000
PharmaceuticalsLarge

360

50
Medium confidence — indicative
EV / EBIT39
Price / Owner Earnings31
Owner Earnings Yield39
Dividend Yield77
Price/Sales29
EV / Gross Profit12
Price/Book26
Return on Capital97
Cash Return on Capital94
Return on Equity83
EBIT Margin97
Gross Profitability68
Cash Conversion12
Accruals54
Owner Earnings Margin96
Sales growth62
Profit Growth90
Long-Term EPS Growth80
Owner Earnings Growth47
Reinvestment18
Price momentum40
Debt load59
Refinancing74
Debt Payback100
Liquidity100
Analyst ratings20
Opinion Changes50
Price Target Upside89
Market mood100
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Chugai Pharmaceutical generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySwitzerland
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeTSE
Founded1943
Employees750
Websitechugai-pharm.co.jp
ISINJP3519400000
Last UpdateApr 2, 2026
Indices
Nikkei 225 (Japan)Renewable Energy UsersTOPIX 100 (Japan)
Themes
Health DiagnosticsArtificial IntelligenceImmunologyInfectious DiseasesNeurologyOsteoporosisCentral Nervous SystemOncologyBiotechnologyClinical TrialsHealth CareMedical

Description

Chugai Pharmaceutical Co., Ltd. (Chugai) is a leading healthcare company established in Japan, primarily engaged in the development and marketing of pharmaceuticals, including biopharmaceuticals. The company emphasizes innovative drug discovery and p…

Analysis

Beloved champion

Chugai Pharmaceutical Co., Ltd. is a beloved champion: its quality is genuine, and the market already prices it as exceptional. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 27.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 11% yearly growth; analysts expect 15%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is uncertain. The company scores 16/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
71
2023202420252026

All-time high

75

Apr 2025

All-time low

41

Jan 2023

Average rank

59

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
29
9
11
24
Price/Earnings
21
28
33
60
Price/Book
26
15
14
18
Dividend Yield
77
53
49
70
Value (overall)
43
18
20
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Chugai Pharmaceutical with its peers
UCB
BRU:UCB
69
CountryBelgium
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Alvotech
NMQ:ALVO
18
CountryLuxembourg
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Roche
VTX:ROG
84
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Dermapharm
GER:DMP
39
CountryGermany
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Inventiva
PAR:IVA
16
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →